Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6113903 | Transfusion and Apheresis Science | 2016 | 5 Pages |
Abstract
There is some preliminary evidence, that veno-occlusive disease prophylaxis with defibrotide (DF) may also have a role in decreasing risk of acute graft-versus-host disease (aGvHD) by preventing tissue damage. In this study, we aimed to investigate the role of DF prophylaxis on the development of aGvHD at Dâ+â180. One hundred ninety-five consecutive adult patients receiving allogeneic HCT were retrospectively evaluated in 3 groups: no DF, DF/post-HCT (DF Dâ+â1 to Dâ+â14) and DF/pre-HCT (DF for 14 days concurrently with conditioning). The total (p: 0.057) and grades III/IV (p: 0.051) aGvHD rates at Dâ+â180 were 46.5%, 40%, 25.5% and 15.5%, 11.2%, 0% in patients on no DF, DF/post-HCT and DF/pre-HCT. DF may have a role in decreasing incidence and severity of aGvHD, especially if used concurrently with conditioning regimen.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Emre Tekgündüz, Ali Hakan Kaya, Sinem Civriz BozdaÄ, Åerife Koçubaba, Ãmür Kayıkçı, Sinem NamdaroÄlu, Bilge UÄur, Seval Akpınar, Hikmetullah Batgi, Filiz Bekdemir, Fevzi AltuntaÅ,